Drug intelligence / Profile preview

bifidobacterium bifidum TMC3115

Development stage: Unknown
Lead developer: Hebei Inatural Biotech
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium bifidum TMC3115 is a **probiotic strain** of B. bifidum originally isolated from healthy infant stools. It is classified as a human “infant-type” bifidobacteria. TMC3115 is developed and used for its modulatory effects on the **gut microbiota**, with research indicating beneficial influence on serum cholesterol metabolism, anti-obesity, anti-allergic effects, and stress modulation via effects on the intestinal immune system and reduction of inflammatory cytokines such as IL-6. The mechanism is thought to involve decomposition of host-derived breast milk oligosaccharides, plant-derived polysaccharides, and mucins, as well as modulation of short-chain fatty acid production and immune mediators (e.g. IL-10, IL-17A)[1][4][5][6].

Other names: bifidobacterium bifidum TMC3115

Targets

IgE (Immunoglobulin E)IL10 (Interleukin-10)IL-6 (Interleukin 6)

Beyond the preview

Go deeper on bifidobacterium bifidum TMC3115.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium bifidum TMC3115.

Explore the full profile